Author: Cyktor, Joshua C.; Carruthers, Bridget; Beamer, Gillian L.; Turner, Joanne
Title: Clonal Expansions of CD8(+) T Cells with IL-10 Secreting Capacity Occur during Chronic Mycobacterium tuberculosis Infection Document date: 2013_3_5
ID: 1rhlu59c_22
Snippet: Anti-CD8 + (53.6.72) depletion antibody (BioXCell) or whole rat IgG2a (2A3) (BioXCell), were diluted to 2.5 mg/ml in PBS and stored at -80uC. Thawed stocks were maintained at 4uC for up to 1 month. Anti-Vb8 (F23.1) antibody-secreting cell line [39] was kindly provided by Dr. Michael Bevan. Antibody administration was modified based on Silva et al. [40] as follows: at day 90 postinfection, 0.5 mg of anti-CD8 + (53.6.72), anti-Vb8 (F23.1), or contr.....
Document: Anti-CD8 + (53.6.72) depletion antibody (BioXCell) or whole rat IgG2a (2A3) (BioXCell), were diluted to 2.5 mg/ml in PBS and stored at -80uC. Thawed stocks were maintained at 4uC for up to 1 month. Anti-Vb8 (F23.1) antibody-secreting cell line [39] was kindly provided by Dr. Michael Bevan. Antibody administration was modified based on Silva et al. [40] as follows: at day 90 postinfection, 0.5 mg of anti-CD8 + (53.6.72), anti-Vb8 (F23.1), or control antibody was injected into the peritoneal cavity of each mouse, followed by 0.5 mg at weekly intervals thereafter until the designated experimental time points. At the initiation of antibody treatment CBA/J mice consistently harbor 6.596 SE 0.12 log 10 Mtb CFU [4] .
Search related documents:
Co phrase search for related documents- Antibody administration and control antibody: 1, 2, 3, 4, 5
- Antibody administration and depletion antibody: 1
- antibody treatment and cell line: 1, 2, 3, 4, 5, 6, 7
- antibody treatment and control antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- antibody treatment and depletion antibody: 1, 2
- cell line and control antibody: 1, 2
- cell line and experimental time: 1, 2, 3
- control antibody and depletion antibody: 1
Co phrase search for related documents, hyperlinks ordered by date